Compare Stocks: MRSN, VECT, ARVN, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.68 +3.3%	$8.06	$6.05 ▼ $14.51	$541.98M	1.71	753,101 shs	2.58 million shs
CTMX CytomX Therapeutics	$3.37 +0.6%	$3.36	$1.72 ▼ $8.21	$570.13M	2.12	3.14 million shs	1.94 million shs
MRSN Mersana Therapeutics	$29.08 +0.1%	$28.83	$5.21 ▼ $30.39	$145.37M	0.44	112,909 shs	712,400 shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+3.33%	+4.58%	+1.05%	-14.14%	+34.99%
CTMX CytomX Therapeutics	+0.60%	+2.74%	-12.24%	-15.33%	+55.30%
MRSN Mersana Therapeutics	0.00%	0.00%	0.00%	0.00%	+334.03%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.68 +3.3%	$8.06	$6.05 ▼ $14.51	$541.98M	1.71	753,101 shs	2.58 million shs
CTMX CytomX Therapeutics	$3.37 +0.6%	$3.36	$1.72 ▼ $8.21	$570.13M	2.12	3.14 million shs	1.94 million shs
MRSN Mersana Therapeutics	$29.08 +0.1%	$28.83	$5.21 ▼ $30.39	$145.37M	0.44	112,909 shs	712,400 shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+3.33%	+4.58%	+1.05%	-14.14%	+34.99%
CTMX CytomX Therapeutics	+0.60%	+2.74%	-12.24%	-15.33%	+55.30%
MRSN Mersana Therapeutics	0.00%	0.00%	0.00%	0.00%	+334.03%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.45	Hold	$14.90	71.66% Upside
CTMX CytomX Therapeutics	3.00	Buy	$12.10	259.05% Upside
MRSN Mersana Therapeutics	1.88	Reduce	$25.92	-10.88% Downside
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRSN, VECT, ARVN, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00
8/5/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$15.00 ➝ $11.00
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
8/4/2026	ARVN Arvinas	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
7/30/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/4/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	2.13	N/A	N/A	$8.71 per share	1.00
CTMX CytomX Therapeutics	$76.20M	7.53	N/A	N/A	$0.58 per share	5.81
MRSN Mersana Therapeutics	$33.18M	4.38	N/A	N/A	($1.92) per share	-15.15
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	86.81	N/A	N/A	2.94%	1.91%	1.29%	N/A
CTMX CytomX Therapeutics	-$17.37M	-$0.41	N/A	N/A	N/A	-166.40%	-36.61%	-28.02%	N/A
MRSN Mersana Therapeutics	-$69.19M	-$13.88	N/A	N/A	N/A	-211.21%	N/A	-65.42%	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MRSN, VECT, ARVN, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
5/11/2026	Q1 2026	ARVN Arvinas	-$0.95	-$0.90	+$0.05	-$0.90	$16.61 million	$15.60 million
5/7/2026	Q1 2026	CTMX CytomX Therapeutics	-$0.14	-$0.10	+$0.04	-$0.10	$4.68 million	$10.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	5.44
CTMX CytomX Therapeutics	N/A	10.38	10.38
MRSN Mersana Therapeutics	N/A	1.39	1.39
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
CTMX CytomX Therapeutics	67.77%
MRSN Mersana Therapeutics	93.92%
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
CTMX CytomX Therapeutics	3.80%
MRSN Mersana Therapeutics	13.00%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
CTMX CytomX Therapeutics	170	170.19 million	163.72 million	Optionable
MRSN Mersana Therapeutics	150	5.00 million	4.35 million	Optionable
VECT VectivBio	30	N/A	N/A	No Data

MRSN, VECT, ARVN, and CTMX Headlines

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln

July 12, 2026 | nasdaq.com

VectivBio Announces Pricing of Initial Public Offering

June 16, 2026 | stockhouse.com

What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story

February 6, 2026 | finance.yahoo.com

Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property

December 23, 2025 | bizjournals.com

Biotech acquired by Ironwood faces allegations of misappropriating trade secrets

November 11, 2025 | bizjournals.com

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.comB

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.comG

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.comM

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth

April 5, 2024 | uk.finance.yahoo.com

FDA approves DMD treatment from Italfarmaco

March 31, 2024 | cen.acs.orgC

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

March 18, 2024 | msn.com

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

March 1, 2024 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, VECT, ARVN, and CTMX Company Descriptions

Arvinas NASDAQ:ARVN

$8.68 +0.28 (+3.33%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$8.79 +0.11 (+1.31%)

As of 05:44 AM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

CytomX Therapeutics NASDAQ:CTMX

$3.37 +0.02 (+0.60%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$3.35 -0.02 (-0.56%)

As of 04:00 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Mersana Therapeutics NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 08/5/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRSN, VECT, ARVN, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRSN, VECT, ARVN, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRSN, VECT, ARVN, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, VECT, ARVN, and CTMX Company Descriptions

Arvinas NASDAQ:ARVN

CytomX Therapeutics NASDAQ:CTMX

Mersana Therapeutics NASDAQ:MRSN

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRSN, VECT, ARVN, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRSN, VECT, ARVN, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRSN, VECT, ARVN, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, VECT, ARVN, and CTMX Company Descriptions

Arvinas NASDAQ:ARVN

CytomX Therapeutics NASDAQ:CTMX

Mersana Therapeutics NASDAQ:MRSN

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools